Drugs & Therapy Perspectives

, Volume 34, Issue 11, pp 528–533 | Cite as

Efficacy of adjuvant treatment with nebulized lidocaine in improving clinical and pulmonary function parameters of acute asthma attacks: a randomized double-blind clinical trial

  • Hassan Motamed
  • Mohammadreza Maleki VerkiEmail author
  • Parviz Mozafari
Original Research Article



Efficient novel medications can facilitate the acute phase of asthma treatment. The aim of this study was to investigate whether nebulized lidocaine as an additional treatment can improve clinical, forced expiratory volume in 1 s (FEV1), and peak expiratory flow rate (PEFR) indexes during an acute asthma attack.


A double-blind randomized clinical trial was conducted in 60 adults with possible acute asthma attack who had been referred to the emergency department of our hospital. Patients were randomized into control and treatment groups. The treatment group received nebulized lidocaine 200 mg at 0, 20, 40, and 60 min after arrival + standard treatment with a single dose of oral prednisolone 50 mg at arrival + nebulized albuterol 2.5 mg and nebulized ipratropium bromide 0.5 mg at 0, 20, 40, and 60 min. The control group received only standard treatment. Clinical severity (Borg Dyspnea Scale), FEV1, and PEFR indexes and hemodynamic parameters were recorded at arrival and at 20-min intervals for 60 min after arrival.


Mean PEFR and FEV1 increased significantly from baseline in both treatment groups, with no significant between-group differences (BGDs). The BGDs in respiratory rate and hemodynamic parameters (heart rate, systolic and diastolic blood pressure, and oxygen saturation) at 0, 20, 40, and 60 min after arrival were not significant (p > 0.05). Finally, the severity of dyspnea (Borg Dyspnea Scale) did not differ between the two groups at discharge (0.68 vs. 0.76; p = 0.566).


The results of this study found no benefit from adding nebulized lidocaine to the standard treatment of asthma attacks. Our data reject any benefits for the efficacy of nebulized lidocaine, at least for short-term use in the acute phase of an asthma attack. Research on the efficacy of nebulized lidocaine during the course of an acute asthma attack is limited, and more research is required to clarify the detailed clinical effects.



The authors thank everyone who helped them conduct the research.

Compliance with Ethical Standards


Financial support for the research was provided by Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Conflicts of interest

Hassan Motamed, Mohammadreza Maleki Verki, and Parviz Mozafari have no conflicts of interest that are directly relevant to the content of this article.

Ethical standards

All procedures were approved by the Ethics Committee of Ahvaz University of Medical Sciences (IR.AJUMS.REC.1394.154) and have, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Patients provided written informed consent before they participated in the study.


  1. 1.
    Sayyah M, Saki-Malehi A, Javanmardi F, Forouzan A, Shirbandi K, Rahim F. Which came first, the risk of migraine or the risk of asthma? A systematic review. Neurol Neurochir Pol. 2018. Scholar
  2. 2.
    Expert Panel Report. 3 (EPR-3). Guidelines for the diagnosis and management of asthma: summary report 2007. J Allergy Clin Immunol. 2007;120:S94–138.CrossRefGoogle Scholar
  3. 3.
    Ivanova JI, Bergman R, Birnbaum HG, et al. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol. 2012;129(5):1229–35.PubMedCrossRefGoogle Scholar
  4. 4.
    Goolsby MJ, Judd DM. Guidelines for the diagnosis and management of asthma: update on selected topics 2002. J Am Acad Nurse Pract. 2003;15(4):151–5.CrossRefGoogle Scholar
  5. 5.
    Barton C, Proudfoot J, Amoroso C, et al. Management of asthma in australian general practice: care is still not in line with clinical practice guidelines. Prim Care Respir J. 2008;18:100–5.CrossRefGoogle Scholar
  6. 6.
    British Thoracic Society Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2014;69(Suppl 1):i1–92.Google Scholar
  7. 7.
    Becker A, Lemière C, Bérubé D, et al. Summary of recommendations from the Canadian asthma consensus guidelines. CMAJ. 2005;173:S3–11.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Kercsmar CM, McDowell KM. Love it or lev it: levalbuterol for severe acute asthma—for now, leave it. J Pediatr. 2009;155(2):162–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Fischl MA, Pitchenik A, Gardner LB. An index predicting relapse and need for hospitalization in patients with acute bronchial asthma. N Engl J Med. 1981;305(14):783–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Hall I. Pharmacogenetics of asthma. Eur Respiratory J. 2000;15(3):449–51.CrossRefGoogle Scholar
  11. 11.
    Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull. 2000;56(4):1054–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Palmer LJ, Silverman ES, Weiss ST, et al. Pharmacogenetics of asthma. Am J Respir Crit Care Med. 2002;165(7):861–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Koga T, Kamimura T, Oshita Y, et al. Determinants of bronchodilator responsiveness in patients with controlled asthma. J Asthma. 2006;43(1):71–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Tsai H-J, Shaikh N, Kho JY, et al. β2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet. 2006;119(5):547.PubMedCrossRefGoogle Scholar
  15. 15.
    Tantisira KG, Hwang ES, Raby BA, et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA. 2004;101(52):18099–104.PubMedCrossRefGoogle Scholar
  16. 16.
    Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004;13(13):1353–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Tantisira KG, Silverman ES, Mariani TJ, et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clinl Immunol. 2007;120(6):1285–91.CrossRefGoogle Scholar
  18. 18.
    Groeben H, Silvanus M-T, Beste M, et al. Both intravenous and inhaled lidocaine attenuate reflex bronchoconstriction but at different plasma concentrations. Am J Respir Crit Care Med. 1999;159(2):530–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Okada S, Hagan JB, Kato M, et al. Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. J Immunol. 1998;160(8):4010–7.PubMedGoogle Scholar
  20. 20.
    Boye N, Bredesen J. Plasma concentrations of lidocaine during inhalation anaesthesia for fiberoptic bronchoscopy. Scand J Respir Dis. 1979;60(3):105–8.PubMedGoogle Scholar
  21. 21.
    Lv Z-M, Chen L, Tang J. Nebulized lidocaine inhalation in the treatment of patients with acute asthma. World J Emerg Med. 2011;2(1):30.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    McCracken JL, Veeranki SP, Ameredes BT, et al. Diagnosis and management of asthma in adults: a review. JAMA. 2017;318(3):279–90.PubMedCrossRefGoogle Scholar
  23. 23.
    Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59–99.PubMedCrossRefGoogle Scholar
  24. 24.
    Serra MF, Anjos-Valotta EA, Olsen PC, et al. Nebulized lidocaine prevents airway inflammation, peribronchial fibrosis, and mucus production in a murine model of asthma. J Am Soc Anesthesiologists. 2012;117(3):580–91.Google Scholar
  25. 25.
    Hunt LW, Frigas E, Butterfield JH, et al. Treatment of asthma with nebulized lidocaine: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2004;113(5):853–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Slaton RM, Thomas RH, Mbathi JW. Evidence for therapeutic uses of nebulized lidocaine in the treatment of intractable cough and asthma. Ann Pharmacother. 2013;47(4):578–85.PubMedCrossRefGoogle Scholar
  27. 27.
    Hunt LW, Swedlund HA, Gleich GJ, editors. Effect of nebulized lidocaine on severe glucocorticoid-dependent asthma. New York: Mayo Clinic Proceedings, Elsevier; 1996.Google Scholar
  28. 28.
    Woolcock AJ. Corticosteroid-resistant asthma: definitions. Am J Respir Crit Care Med. 1996;154:S45–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Harrison T, Tattersfield A. Effect of single doses of inhaled lignocaine on FEV1 and bronchial reactivity in asthma. Respir Med. 1998;92(12):1359–63.PubMedCrossRefGoogle Scholar
  30. 30.
    Gao Z-Y, Li P-K, Zhao J-Z, et al. Effects of airborne fine particulate matter on human respiratory symptoms and pulmonary function. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2010;28(10):748–51.PubMedGoogle Scholar
  31. 31.
    Groeben H, Silvanus M-T, Beste M. Combined lidocaine and salbutamol inhalation for airway anesthesia markedly protects against reflex bronchoconstriction. Chest. 2000;118(2):509–15.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Hassan Motamed
    • 1
  • Mohammadreza Maleki Verki
    • 1
    Email author
  • Parviz Mozafari
    • 1
  1. 1.Emergency Medicine DepartmentAhvaz Jundishapur University of Medical SciencesAhvazIran

Personalised recommendations